

	MTARTECH IN
Equity Shares (m)	31
M.Cap.(INRb)/(USDb)	51.2 / 0.6
52-Week Range (INR)	2200 / 1152
1, 6, 12 Rel. Per (%)	14/-/9/-29
12M Avg Val (INR M)	425

**Financials & Valuations (INR b)**

Y/E Mar	2025	2026E	2027E
Sales	6.8	8.7	11.4
EBITDA	1.2	1.9	2.7
Adj. PAT	0.5	1.1	1.7
EBITDA Margin (%)	17.9	21.5	23.5
Cons. Adj. EPS (INR)	17.2	34.8	55.4
EPS Gr. (%)	-5.8	102.5	59.0
BV/Sh. (INR)	237.0	271.8	327.2
<b>Ratios</b>			
Net D:E	0.2	0.1	0.1
RoE (%)	7.5	13.7	18.5
RoCE (%)	7.8	12.8	17.3
<b>Valuations</b>			
P/E (x)	96.3	47.6	29.9
EV/EBITDA (x)	43.5	27.8	19.3

**Shareholding pattern (%)**

As on	Mar-25	Dec-24	Mar-24
Promoter	31.8	31.4	37.3
DII	24.4	23.2	18.1
FII	6.7	7.0	10.6
Others	37.1	38.4	34.1

Note: FII includes depository receipts

**CMP: INR1,663      TP: INR1,950 (+17%)**
**Buy**
**Healthy revenue growth but below guidance**
**Operating performance missed our estimates**

- MTARTECH reported strong revenue/EBITDA growth of 28%/87% YoY in 4QFY25 (on low base), led by increasing wallet share from existing clients and onboarding of new customers. This growth was largely led by clean energy fuel cells (up 38%), followed by Products segment (up 77% YoY) and Aerospace (up 59%).
- However, the company fell short of its FY25 revenue/EBITDA margin guidance of INR7b+/21%+ (+/- 100bp) and ended FY25 with revenue of INR6.7b and EBITDA margins of 17.9%. This was due to the deferment of some Aerospace orders (high margin) and order hiatus amid geopolitical uncertainties (tariffs). As a result, MTARTECH has lowered its FY26 guidance for revenue growth to 25% (vs. 30% earlier) and EBITDA margins to 21% (+/- 100bp) from 24% (+/- 200bp) earlier.
- Factoring in lower-than-expected 4Q performance and lower guidance, we reduce our FY26/FY27 EPS estimates by 20%/21%. We retain our BUY rating on the stock with a TP of INR1,950 (35x FY27E EPS).

**Margin improves YoY led by better gross margins (product mix)**

- Consolidated revenue grew 28% YoY/5% QoQ to INR1.8b (est. INR2.2b). EBITDA grew 87% YoY/3% QoQ to INR341m (est. INR558m).
- EBITDA margin expanded 590bp YoY but contracted 40bp QoQ to 18.7% (est. 25.7%). Gross margin stood at 52.3% (+700bp YoY). Employee expenses/other expenses as % of sales stood at 18.8%/14.8% (+110bp/-10bp YoY).
- Clean Energy - Fuel Cell/AeroSpace & Defence (A&D)/Products & others revenue grew 38%/59%/77% YoY to INR1.1b/INR331m/INR377m. Revenue from Clean Energy - Nuclear declined 88% YoY to INR26m.
- The order book as of Mar'25 stood at INR9.8b, with inflows of ~INR1.3b in 4QFY25. The order book mix was ~48%/16%/28%/7% for Clean Energy – Fuel Cell/Clean energy - Nuclear/A&D/Product & others. A&D witnessed the highest YoY growth in its order book (44%).
- NWC days as of Mar'25 jumped to 229 from 222 in Dec'24, largely due to a jump in receivables days to 113 (vs. 97), which was partly offset by an increase in payable days to 77 (vs. 71). Inventory days stood flat at 186.
- In FY25, revenue/EBITDA grew 16%/7% YoY to INR6.8b/INR1.2b, while adj. PAT declined by 5.8% YoY to INR529m.

## Highlights from the management commentary

- **Clean energy:** The company guided for revenue growth of 20% YoY, driven by momentum in fuel cells, battery storage, and hydropower. For Fluence, Proto-1 for battery storage is complete, and Proto-2 is underway with design revisions. A long-term supply agreement with Fluence is expected in 1Q/2QFY26, which will trigger volume production.
- **Nuclear:** The company has guided for revenue of INR600m in FY26, driven by long-term projects such as FMBC and fuel transfer systems. It expects imminent orders from NPCIL and government agencies for the refurbishment of five reactors. Additionally, it is pursuing a significant INR7-8b opportunity from the upcoming nuclear expansion initiatives, including component supplies for the Bharat 220 MW modular reactor.
- **Aerospace:** The company reported FY25 revenue of INR930m, driven by key contracts from ISRO, DRDO, GKN, Talis, and Elbit. It has guided for revenue of INR1.45b in FY26, supported by qualification orders, defense tender execution, and rising export demand.

## Valuation and view


- With an order book of INR9.8b as of Mar'25 and a healthy pipeline across Clean Energy, A&D, and Nuclear sectors, we anticipate healthy growth and margin expansion in the coming years, driven by a scale-up in high-margin businesses and new product ramp-ups.
- We estimate a CAGR of 30%/49%/79% in revenue/EBITDA/adj. PAT over FY25-FY27. We retain our BUY rating on the stock with a TP of INR1,950 (35x FY27E EPS).

## Consolidated - Quarterly Earning Model


Y/E March									(INRm)		
	FY24				FY25				FY24	FY25E	FY25 4QE
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			
<b>Gross Sales</b>	<b>1,526</b>	<b>1,668</b>	<b>1,184</b>	<b>1,430</b>	<b>1,283</b>	<b>1,902</b>	<b>1,745</b>	<b>1,831</b>	<b>5,808</b>	<b>6,760</b>	<b>2,173</b>
YoY Change (%)	67.6	32.2	-26.1	-27.2	-15.9	14.0	47.4	28.1	1.2	16.4	52.0
<b>Total Expenditure</b>	<b>1,180</b>	<b>1,307</b>	<b>945</b>	<b>1,247</b>	<b>1,117</b>	<b>1,534</b>	<b>1,412</b>	<b>1,489</b>	<b>4,681</b>	<b>5,552</b>	<b>1,615</b>
<b>EBITDA</b>	<b>345</b>	<b>361</b>	<b>239</b>	<b>182</b>	<b>166</b>	<b>368</b>	<b>333</b>	<b>341</b>	<b>1,127</b>	<b>1,208</b>	<b>558</b>
Margins (%)	22.6	21.6	20.2	12.7	12.9	19.4	19.1	18.7	19.4	17.9	25.7
Depreciation	56	58	58	59	61	78	87	96	232	322	90
Interest	57	55	56	55	48	52	63	59	223	222	60
Other Income	41	8	5	4	5	14	31	0	58	52	35
<b>PBT before EO expense</b>	<b>273</b>	<b>257</b>	<b>129</b>	<b>72</b>	<b>62</b>	<b>253</b>	<b>214</b>	<b>186</b>	<b>730</b>	<b>716</b>	<b>443</b>
<b>PBT</b>	<b>273</b>	<b>257</b>	<b>129</b>	<b>72</b>	<b>62</b>	<b>253</b>	<b>214</b>	<b>186</b>	<b>730</b>	<b>716</b>	<b>443</b>
Tax	69	52	24	23	18	65	55	49	169	187	112
Rate (%)	25.4	20.3	18.9	32.2	28.6	25.8	25.5	26.3	23.2	26.1	25.2
<b>Reported PAT</b>	<b>203</b>	<b>205</b>	<b>104</b>	<b>49</b>	<b>44</b>	<b>188</b>	<b>160</b>	<b>137</b>	<b>561</b>	<b>529</b>	<b>331</b>
<b>Adj PAT</b>	<b>203</b>	<b>205</b>	<b>104</b>	<b>49</b>	<b>44</b>	<b>188</b>	<b>160</b>	<b>137</b>	<b>561</b>	<b>529</b>	<b>331</b>
YoY Change (%)	25.4	-17.1	-66.8	-84.3	-78.2	-8.2	52.8	181.7	-45.7	-5.8	580.4
Margins (%)	13.3	12.3	8.8	3.4	3.5	9.9	9.2	7.5	9.7	7.8	15.3

## Key Exhibits


### Exhibit 1: Consolidated order book trend




### Exhibit 2: Consolidated revenue trend




### Exhibit 3: Consolidated EBITDA trend




### Exhibit 4: Consolidated adj. PAT trend




### Exhibit 5: Segment-wise order book mix




### Exhibit 6: Product and Others revenue trend




**Exhibit 7: Clean Energy – Civil Nuclear power revenue trend**



**Exhibit 8: A&D segment revenue trend**



**Exhibit 9: Clean Energy – Fuel Cells, Hydel and Others revenue trend**





## Highlights from the management commentary

### Overall guidance

- The company is targeting 25% revenue growth in FY26 and healthy EBITDA margins of ~21% ( $\pm 100\text{bp}$ ), driven by operational efficiency and strong demand visibility.
- This guidance excludes upside from multiple opportunities, including EMAs for Tejas aircraft, nuclear tenders, and Fluence battery storage orders.
- In FY26, margin expansion is anticipated to be driven by operating leverage, scale-up of high-margin sectors (especially A&D) and the successful ramp-up of recently developed, higher-value products.
- The company has delivered multiple first articles and prototype units to prominent multinational clients, including Clearance, Weatherford, IIG, and others, underscoring its growing reputation and technical capabilities.
- The focus remains on securing long-term contracts in high-growth sectors like Clean Energy, Oil & Gas, and Aerospace, while simultaneously investing in internal capacity enhancements to reduce reliance on outsourcing.

### Clean Energy

- The company reported FY25 revenue of INR4.7b, with a strong order book of INR3.49b already secured, providing healthy revenue visibility heading into FY26.
- FY26 revenue is guided to grow 15-20% YoY, led by increasing traction across key verticals such as fuel cells, battery storage, and hydropower.
- Proto-1 for battery storage has been successfully completed, while Proto-2 is currently underway with ongoing design revisions.
- A long-term supply agreement with Fluence is anticipated in 1Q/2QFY26, with mass production to commence post-signing. Additionally, the electrolyzer (currently not factored into projections) presents a significant upside opportunity.

### Nuclear

- The company reported revenue of INR190m in FY25 and has guided for a strong increase to INR600m in FY26, supported by long-term projects such as FMBC systems and fuel transfer systems.
- Orders from NPCIL and government bodies for the refurbishment of five reactors across Tarapur, Rajasthan, Madhya Pradesh, and Taiga are expected shortly.
- The company is actively targeting an opportunity worth INR7-8b from the upcoming nuclear expansion projects, including the Bharat 220 MW modular reactor component supply.

### A&D

- The company reported revenue of INR930m in FY25, supported by key contracts from ISRO, DRDO, GKN, Talis, and Elbit.
- It has guided for ~80% YoY revenue growth in FY26, led by qualification orders, execution of defense tenders, and increasing export demand.
- Development and certification of EMAs for the Tejas aircraft are in advanced stages, with volume ramp-up anticipated in the near term.

- The company has received NASCAP certification, positioning MTAR as a qualified single-window supplier for global OEMs.

### Products

- The company recorded revenue of INR1.48b in FY25 and has guided for 20% YoY growth in FY26, driven by expanding product portfolio and customer base.
- It has developed several import-substitute products, including roller screws, VMAs, electromechanical actuators, and special valves, strengthening its position in the domestic supply chain.
- Multiple products are currently under first article validation, with several nearing qualification or commercialization, indicating a strong pipeline for future revenue visibility.

### Order book

- The company recorded FY25 order inflows of INR7.2b, with key contributions from Clean Energy (INR3.49b), A&D (INR1.78b), and Nuclear (INR1.55b).
- It has set a robust order backlog target of INR15b for FY26, supported by deferred orders for Taiga Units 5 & 6 and strong visibility from the upcoming tenders.
- Management highlighted an additional upside potential of INR7-8b from modular reactor components and reactor refurbishment orders, which are not yet factored into the FY26 plan.

### Capex, working capital and debt profile

- The company incurred a capex of INR1b in FY25 and plans to invest INR500–600m in FY26, focusing on resolving capacity bottlenecks and expanding high-margin business segments.
- Additional capex may be required for long-term strategic projects, contingent on final agreement sign-offs.
- Net working capital cycle improved to 229 days in FY25, with targets to reduce it further to 200 days in FY26 and 175 days by FY27.
- Long-term debt declined by INR150m to INR1.27b, with INR460m scheduled for repayment in FY26; the company aims to repay 80% of its total debt by FY27.

### Other

- The Vedapur oil & gas project is nearing first article completion, with a long-term agreement expected in 1QFY26. Volume production will follow, leveraging infrastructure on pre-acquired land.
- MTAR is assembling battery storage systems (excluding batteries) for Fluence's US projects. With one prototype complete and another underway, a long-term deal is expected by 2QFY26 to enable a scale-up.
- Substantial FY27 revenue is anticipated from the Fluence deal, though final figures await pricing clarity.
- MTAR's portfolio aligns with India's strategic push for self-reliance across clean energy, defense, aerospace, and nuclear sectors. A new unit commissioned in FY25 will aid future expansion.

### Valuation and view

- With an order book of INR9.8b as of Mar'25 and a healthy pipeline across Clean Energy, A&D, and Nuclear sectors, we anticipate healthy growth and margin expansion in coming years, driven by a scale-up in high-margin businesses and new product ramp-ups.
- We estimate a CAGR of 30%/49%/79% in revenue/EBITDA/adj. PAT over FY25-FY27. We retain our BUY rating on the stock with a TP of INR1,950 (35x FY27E EPS).

### Exhibit 10: Changes in earnings estimates

Earnings change (INR m)	Old		New		Change	
	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Revenue	9,224	12,064	8,707	11,370	-6%	-6%
EBITDA	2,168	3,161	1,872	2,672	-14%	-15%
Adj. PAT	1,332	2,147	1,071	1,703	-20%	-21%

## Financials and valuations

Consolidated - Income Statement									(INRm)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>Total Income from Operations</b>	<b>1,837</b>	<b>2,138</b>	<b>2,464</b>	<b>3,220</b>	<b>5,738</b>	<b>5,808</b>	<b>6,760</b>	<b>8,707</b>	<b>11,370</b>
Change (%)	15	16	15	31	78	1	16	29	31
RM Cost	708	835	912	1,163	2,695	3,024	3,419	4,354	5,685
Employees Cost	435	516	530	708	935	970	1,238	1,437	1,706
Other Expenses	157	208	192	406	568	687	895	1,045	1,308
<b>Total Expenditure</b>	<b>1,300</b>	<b>1,558</b>	<b>1,634</b>	<b>2,276</b>	<b>4,198</b>	<b>4,681</b>	<b>5,552</b>	<b>6,835</b>	<b>8,698</b>
<b>EBITDA</b>	<b>537</b>	<b>580</b>	<b>831</b>	<b>944</b>	<b>1,540</b>	<b>1,127</b>	<b>1,208</b>	<b>1,872</b>	<b>2,672</b>
Margin (%)	29.2	27.1	33.7	29.3	26.8	19.4	17.9	21.5	23.5
Depreciation	112	121	126	143	187	232	322	341	370
<b>EBIT</b>	<b>425</b>	<b>459</b>	<b>705</b>	<b>801</b>	<b>1,353</b>	<b>895</b>	<b>886</b>	<b>1,531</b>	<b>2,302</b>
Int. and Finance Charges	45	48	70	66	146	223	222	170	117
Other Income	35	44	13	88	195	58	52	70	91
<b>PBT after EO Exp.</b>	<b>415</b>	<b>455</b>	<b>648</b>	<b>822</b>	<b>1,402</b>	<b>730</b>	<b>716</b>	<b>1,431</b>	<b>2,276</b>
Total Tax	24	142	188	213	368	169	187	360	573
Tax Rate (%)	5.7	31.2	29.0	26.0	26.2	23.2	26.1	25.2	25.2
<b>Reported PAT</b>	<b>392</b>	<b>313</b>	<b>461</b>	<b>609</b>	<b>1,034</b>	<b>561</b>	<b>529</b>	<b>1,071</b>	<b>1,703</b>
<b>Adjusted PAT</b>	<b>392</b>	<b>313</b>	<b>461</b>	<b>609</b>	<b>1,034</b>	<b>561</b>	<b>529</b>	<b>1,071</b>	<b>1,703</b>
Change (%)	625.7	-20.1	47.1	32.2	69.9	-45.7	-5.8	102.5	59.0
Margin (%)	21.3	14.6	18.7	18.9	18.0	9.7	7.8	12.3	15.0

Consolidated - Balance Sheet									(INRm)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	282	268	308	308	308	308	308	308	308
Total Reserves	2,068	1,983	4,460	4,890	5,894	6,456	6,982	8,053	9,756
<b>Net Worth</b>	<b>2,350</b>	<b>2,251</b>	<b>4,768</b>	<b>5,197</b>	<b>6,201</b>	<b>6,763</b>	<b>7,289</b>	<b>8,360</b>	<b>10,063</b>
Total Loans	287	291	170	959	1,434	1,909	1,773	1,313	913
Deferred Tax Liabilities	0	53	127	163	182	209	224	224	224
<b>Capital Employed</b>	<b>2,638</b>	<b>2,595</b>	<b>5,064</b>	<b>6,319</b>	<b>7,817</b>	<b>8,881</b>	<b>9,285</b>	<b>9,897</b>	<b>11,200</b>
Gross Block	1,978	2,028	2,273	2,710	3,842	4,569	5,873	6,498	6,943
Less: Accum. Deprn.	356	477	603	746	932	1,164	1,486	1,827	2,197
<b>Net Fixed Assets</b>	<b>1,622</b>	<b>1,551</b>	<b>1,671</b>	<b>1,964</b>	<b>2,910</b>	<b>3,405</b>	<b>4,387</b>	<b>4,671</b>	<b>4,746</b>
Capital WIP	56	117	105	438	644	729	532	306	261
<b>Total Investments</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>623</b>	<b>275</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Curr. Assets, Loans&amp;Adv.</b>	<b>1,373</b>	<b>1,794</b>	<b>4,087</b>	<b>4,252</b>	<b>6,804</b>	<b>5,942</b>	<b>6,384</b>	<b>7,395</b>	<b>9,312</b>
Inventory	411	755	1,025	1,703	3,866	3,476	3,461	4,294	5,452
Account Receivables	504	616	773	1,360	2,084	1,466	2,098	2,266	2,804
Cash and Bank Balance	108	233	1,909	669	312	508	169	138	147
Loans and Advances	351	191	380	520	543	492	657	697	910
<b>Curr. Liability &amp; Prov.</b>	<b>414</b>	<b>868</b>	<b>799</b>	<b>958</b>	<b>2,816</b>	<b>1,196</b>	<b>2,017</b>	<b>2,476</b>	<b>3,120</b>
Account Payables	60	306	371	570	2,182	714	1,061	1,431	1,869
Other Current Liabilities	329	495	397	353	559	422	872	958	1,137
Provisions	26	67	32	35	75	59	85	87	114
<b>Net Current Assets</b>	<b>959</b>	<b>927</b>	<b>3,288</b>	<b>3,294</b>	<b>3,989</b>	<b>4,747</b>	<b>4,367</b>	<b>4,919</b>	<b>6,192</b>
<b>Appl. of Funds</b>	<b>2,638</b>	<b>2,595</b>	<b>5,064</b>	<b>6,319</b>	<b>7,817</b>	<b>8,881</b>	<b>9,285</b>	<b>9,897</b>	<b>11,200</b>

## Financials and valuations

### Ratios

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>Basic (INR)</b>									
EPS	13.9	11.7	15.0	19.8	33.6	18.2	17.2	34.8	55.4
Cash EPS	17.9	16.2	19.1	24.4	39.7	25.8	27.7	45.9	67.4
BV/Share	83.3	84.1	155.0	169.0	201.6	219.9	237.0	271.8	327.2
<b>Valuation (x)</b>									
P/E	119.2	141.5	110.6	83.7	49.3	90.8	96.3	47.6	29.9
Cash P/E	92.7	102.2	86.9	67.7	41.7	64.2	59.8	36.1	24.6
P/BV	19.9	19.7	10.7	9.8	8.2	7.5	7.0	6.1	5.1
EV/Sales	25.5	20.8	20.0	15.7	9.0	9.0	7.8	6.0	4.5
EV/EBITDA	87.3	76.6	59.2	53.6	33.6	46.4	43.5	27.8	19.3
FCF per share	6.3	16.6	-4.6	-39.3	-32.6	-11.8	0.7	17.2	14.1
<b>Return Ratios (%)</b>									
RoE	17.8	13.6	13.1	12.2	18.1	8.7	7.5	13.7	18.5
RoCE	17.7	13.4	13.6	11.9	16.6	9.0	7.8	12.8	17.3
RoIC	17.0	13.4	18.9	15.5	17.9	9.7	8.1	12.7	17.0
<b>Working Capital Ratios</b>									
Fixed Asset Turnover (x)	0.9	1.1	1.1	1.2	1.5	1.3	1.2	1.3	1.6
Asset Turnover (x)	0.7	0.8	0.5	0.5	0.7	0.7	0.7	0.9	1.0
Inventory (Days)	82	129	152	193	246	218	187	180	175
Debtor (Days)	100	105	114	154	133	92	113	95	90
Creditor (Days)	12	52	55	65	139	45	57	60	60
<b>Leverage Ratio (x)</b>									
Current Ratio	3.3	2.1	5.1	4.4	2.4	5.0	3.2	3.0	3.0
Interest Cover Ratio	9.5	9.6	10.1	12.0	9.3	4.0	4.0	9.0	19.7
Net Debt/Equity	0.1	0.0	-0.4	-0.1	0.1	0.2	0.2	0.1	0.1

### Consolidated - Cash Flow Statement

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
OP/(Loss) before Tax	416	455	648	822	1,402	730	716	1,431	2,276
Depreciation	112	121	126	143	187	232	322	341	370
Interest & Finance Charges	38	38	57	66	146	165	222	100	26
Direct Taxes Paid	-94	-72	-117	-180	-323	-213	-134	-360	-573
(Inc)/Dec in WC	-57	26	-617	-1,079	-1,291	-372	-89	-583	-1,264
<b>CF from Operations</b>	<b>415</b>	<b>567</b>	<b>97</b>	<b>-227</b>	<b>121</b>	<b>543</b>	<b>1,036</b>	<b>929</b>	<b>835</b>
Others	7	-5	-11	-71	-47	31	-24	0	0
<b>CF from Operating incl EO</b>	<b>421</b>	<b>562</b>	<b>86</b>	<b>-298</b>	<b>74</b>	<b>574</b>	<b>1,013</b>	<b>929</b>	<b>835</b>
(Inc)/Dec in FA	-243	-119	-228	-911	-1,078	-938	-990	-400	-400
<b>Free Cash Flow</b>	<b>178</b>	<b>443</b>	<b>-142</b>	<b>-1,209</b>	<b>-1,004</b>	<b>-364</b>	<b>23</b>	<b>529</b>	<b>435</b>
(Pur)/Sale of Investments	0	0	0	-780	377	298	-48	0	0
Others	-86	-2	8	241	-166	83	11	70	91
<b>CF from Investments</b>	<b>-329</b>	<b>-121</b>	<b>-220</b>	<b>-1,450</b>	<b>-867</b>	<b>-556</b>	<b>-1,027</b>	<b>-330</b>	<b>-309</b>
Issue of Shares	0	0	2,127	0	0	0	0	0	0
Inc/(Dec) in Debt	90	-5	-122	789	457	476	-137	-460	-400
Interest Paid	-62	-59	-64	0	-137	-223	-222	-170	-117
Dividend Paid	-102	-170	-80	-185	0	0	0	0	0
Others	0	-179	-60	-64	0	0	0	0	0
<b>CF from Fin. Activity</b>	<b>-75</b>	<b>-414</b>	<b>1,802</b>	<b>541</b>	<b>320</b>	<b>253</b>	<b>-358</b>	<b>-630</b>	<b>-517</b>
<b>Inc/Dec of Cash</b>	<b>17</b>	<b>28</b>	<b>1,667</b>	<b>-1,207</b>	<b>-473</b>	<b>270</b>	<b>-373</b>	<b>-31</b>	<b>9</b>
Opening Balance	91	108	233	1,909	670	312	508	169	138
Other cash & cash equivalent	0	97	9	-32	116	-74	34		
<b>Closing Balance</b>	<b>108</b>	<b>233</b>	<b>1,909</b>	<b>670</b>	<b>312</b>	<b>508</b>	<b>169</b>	<b>138</b>	<b>147</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

## NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERI, COMRIS and CCR and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/ListOf%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal Capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal Capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).  
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.

9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### **Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### **Terms & Conditions:**

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no warranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### **Disclaimer:**

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; [www.motilaloswal.com](http://www.motilaloswal.com). Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to [query@motilaloswal.com](mailto:query@motilaloswal.com). In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com), for DP to [dpgrivances@motilaloswal.com](mailto:dpgrivances@motilaloswal.com).